Pre-order Enquiry
Request Free Sample
Global Neurodegenerative Disorder Therapeutics Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application
SKU ID : QYR-18704032 | Publishing Date : 07-Jul-2021 | No. of pages : 111
Detailed TOC of Global Neurodegenerative Disorder Therapeutics Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application
1 Market Overview of Neurodegenerative Disorder Therapeutics1.1 Neurodegenerative Disorder Therapeutics Market Overview
1.1.1 Neurodegenerative Disorder Therapeutics Product Scope
1.1.2 Neurodegenerative Disorder Therapeutics Market Status and Outlook
1.2 Global Neurodegenerative Disorder Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2027)
1.4 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Neurodegenerative Disorder Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
1.6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
1.6.2 Europe Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
1.6.4 Latin America Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
2 Neurodegenerative Disorder Therapeutics Market Overview by Type
2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 Immunomodulators
2.5 Interferons
2.6 Decarboxylase Inhibitors
2.7 Dopamine Agonists
2.8 Others
3 Neurodegenerative Disorder Therapeutics Market Overview by Application
3.1 Global Neurodegenerative Disorder Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Multiple Sclerosis
3.5 Parkinson'S Disease
3.6 Alzheimer'S Disease
3.7 Spinal Muscular Atrophy
3.8 Huntington Disease
3.9 Other Neurodegenerative Disorders
4 Neurodegenerative Disorder Therapeutics Competition Analysis by Players
4.1 Global Neurodegenerative Disorder Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2020)
4.3 Date of Key Players Enter into Neurodegenerative Disorder Therapeutics Market
4.4 Global Top Players Neurodegenerative Disorder Therapeutics Headquarters and Area Served
4.5 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Neurodegenerative Disorder Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Biogen, Inc.
5.1.1 Biogen, Inc. Profile
5.1.2 Biogen, Inc. Main Business
5.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.1.4 Biogen, Inc. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 Biogen, Inc. Recent Developments
5.2 Pfizer, Inc.
5.2.1 Pfizer, Inc. Profile
5.2.2 Pfizer, Inc. Main Business
5.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.2.4 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 Pfizer, Inc. Recent Developments
5.3 Novartis AG
5.5.1 Novartis AG Profile
5.3.2 Novartis AG Main Business
5.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.3.4 Novartis AG Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 Sanofi S.A. Recent Developments
5.4 Sanofi S.A.
5.4.1 Sanofi S.A. Profile
5.4.2 Sanofi S.A. Main Business
5.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.4.4 Sanofi S.A. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 Sanofi S.A. Recent Developments
5.5 Teva Pharmaceutical Industries Ltd.
5.5.1 Teva Pharmaceutical Industries Ltd. Profile
5.5.2 Teva Pharmaceutical Industries Ltd. Main Business
5.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5.6 UCB S.A.
5.6.1 UCB S.A. Profile
5.6.2 UCB S.A. Main Business
5.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.6.4 UCB S.A. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.6.5 UCB S.A. Recent Developments
5.7 F. Hoffmann- La Roche Ltd.
5.7.1 F. Hoffmann- La Roche Ltd. Profile
5.7.2 F. Hoffmann- La Roche Ltd. Main Business
5.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.7.4 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.7.5 F. Hoffmann- La Roche Ltd. Recent Developments
5.8 H. Lundbeck
5.8.1 H. Lundbeck Profile
5.8.2 H. Lundbeck Main Business
5.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.8.4 H. Lundbeck Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.8.5 H. Lundbeck Recent Developments
5.9 Merck KGaA
5.9.1 Merck KGaA Profile
5.9.2 Merck KGaA Main Business
5.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.9.4 Merck KGaA Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.9.5 Merck KGaA Recent Developments
5.10 GlaxoSmithKline PLC
5.10.1 GlaxoSmithKline PLC Profile
5.10.2 GlaxoSmithKline PLC Main Business
5.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.10.4 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.10.5 GlaxoSmithKline PLC Recent Developments
5.11 AbbVie Inc.
5.11.1 AbbVie Inc. Profile
5.11.2 AbbVie Inc. Main Business
5.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.11.4 AbbVie Inc. Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.11.5 AbbVie Inc. Recent Developments
5.12 Bristol Myers Squibb Company
5.12.1 Bristol Myers Squibb Company Profile
5.12.2 Bristol Myers Squibb Company Main Business
5.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.12.4 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.12.5 Bristol Myers Squibb Company Recent Developments
5.13 Boehringer Ingeiheim International GmbH
5.13.1 Boehringer Ingeiheim International GmbH Profile
5.13.2 Boehringer Ingeiheim International GmbH Main Business
5.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.13.4 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.13.5 Boehringer Ingeiheim International GmbH Recent Developments
5.14 Bayer AG
5.14.1 Bayer AG Profile
5.14.2 Bayer AG Main Business
5.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.14.4 Bayer AG Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.14.5 Bayer AG Recent Developments
5.15 Eisai Co., Ltd
5.15.1 Eisai Co., Ltd Profile
5.15.2 Eisai Co., Ltd Main Business
5.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Products, Services and Solutions
5.15.4 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Revenue (US$ Million) & (2016-2021)
5.15.5 Eisai Co., Ltd Recent Developments
6 North America
6.1 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neurodegenerative Disorder Therapeutics Market Dynamics
11.1 Neurodegenerative Disorder Therapeutics Industry Trends
11.2 Neurodegenerative Disorder Therapeutics Market Drivers
11.3 Neurodegenerative Disorder Therapeutics Market Challenges
11.4 Neurodegenerative Disorder Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
List of Figures, Tables and Charts Available in Global Neurodegenerative Disorder Therapeutics Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application
List of TablesTable 1. Global Market Neurodegenerative Disorder Therapeutics Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027
Table 2. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 3. Global Neurodegenerative Disorder Therapeutics Market Size Share by Region (2016-2021)
Table 4. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2022-2027) & (US$ Million)
Table 5. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size Share by Region (2022-2027)
Table 6. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) & (US$ Million)
Table 8. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2016-2021)
Table 9. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2022-2027) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2022-2027)
Table 11. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027
Table 12. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) & (US$ Million)
Table 13. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2016-2021)
Table 14. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2022-2027) & (US$ Million)
Table 15. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2022-2027)
Table 16. Global Neurodegenerative Disorder Therapeutics Revenue (US$ Million) by Players (2016-2021)
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2016-2021)
Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2020)
Table 19. Date of Key Manufacturers Enter into Neurodegenerative Disorder Therapeutics Market
Table 20. Global Neurodegenerative Disorder Therapeutics Top Players Headquarters and Area Served
Table 21. Neurodegenerative Disorder Therapeutics Product Solution and Service
Table 22. Global Neurodegenerative Disorder Therapeutics Players Market Concentration Ratio (CR5 and HHI)
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Biogen, Inc. Basic Information List
Table 25. Biogen, Inc. Description and Business Overview
Table 26. Biogen, Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 27. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Biogen, Inc. (2016-2021)
Table 28. Biogen, Inc. Recent Developments
Table 29. Pfizer, Inc. Basic Information List
Table 30. Pfizer, Inc. Description and Business Overview
Table 31. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 32. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Pfizer, Inc. (2016-2021)
Table 33. Pfizer, Inc. Recent Developments
Table 34. Novartis AG Basic Information List
Table 35. Novartis AG Description and Business Overview
Table 36. Novartis AG Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 37. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Novartis AG (2016-2021)
Table 38. Novartis AG Recent Developments
Table 39. Sanofi S.A. Basic Information List
Table 40. Sanofi S.A. Description and Business Overview
Table 41. Sanofi S.A. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 42. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Sanofi S.A. (2016-2021)
Table 43. Sanofi S.A. Recent Developments
Table 44. Teva Pharmaceutical Industries Ltd. Basic Information List
Table 45. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 46. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 47. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Teva Pharmaceutical Industries Ltd. (2016-2021)
Table 48. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 49. UCB S.A. Basic Information List
Table 50. UCB S.A. Description and Business Overview
Table 51. UCB S.A. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 52. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of UCB S.A. (2016-2021)
Table 53. UCB S.A. Recent Developments
Table 54. F. Hoffmann- La Roche Ltd. Basic Information List
Table 55. F. Hoffmann- La Roche Ltd. Description and Business Overview
Table 56. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 57. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of F. Hoffmann- La Roche Ltd. (2016-2021)
Table 58. F. Hoffmann- La Roche Ltd. Recent Developments
Table 59. H. Lundbeck Basic Information List
Table 60. H. Lundbeck Description and Business Overview
Table 61. H. Lundbeck Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 62. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of H. Lundbeck (2016-2021)
Table 63. H. Lundbeck Recent Developments
Table 64. Merck KGaA Basic Information List
Table 65. Merck KGaA Description and Business Overview
Table 66. Merck KGaA Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 67. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Merck KGaA (2016-2021)
Table 68. Merck KGaA Recent Developments
Table 69. GlaxoSmithKline PLC Basic Information List
Table 70. GlaxoSmithKline PLC Description and Business Overview
Table 71. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 72. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of GlaxoSmithKline PLC (2016-2021)
Table 73. GlaxoSmithKline PLC Recent Developments
Table 74. AbbVie Inc. Basic Information List
Table 75. AbbVie Inc. Description and Business Overview
Table 76. AbbVie Inc. Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 77. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of AbbVie Inc. (2016-2021)
Table 78. AbbVie Inc. Recent Developments
Table 79. Bristol Myers Squibb Company Basic Information List
Table 80. Bristol Myers Squibb Company Description and Business Overview
Table 81. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 82. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Bristol Myers Squibb Company (2016-2021)
Table 83. Bristol Myers Squibb Company Recent Developments
Table 84. Boehringer Ingeiheim International GmbH Basic Information List
Table 85. Boehringer Ingeiheim International GmbH Description and Business Overview
Table 86. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 87. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Boehringer Ingeiheim International GmbH (2016-2021)
Table 88. Boehringer Ingeiheim International GmbH Recent Developments
Table 89. Bayer AG Basic Information List
Table 90. Bayer AG Description and Business Overview
Table 91. Bayer AG Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 92. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Bayer AG (2016-2021)
Table 93. Bayer AG Recent Developments
Table 94. Eisai Co., Ltd Basic Information List
Table 95. Eisai Co., Ltd Description and Business Overview
Table 96. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Products, Services and Solutions
Table 97. Revenue (US$ Million) in Neurodegenerative Disorder Therapeutics Business of Eisai Co., Ltd (2016-2021)
Table 98. Eisai Co., Ltd Recent Developments
Table 99. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 100. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 101. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 102. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 103. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 104. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 105. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2016-2021)
Table 106. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2022-2027)
Table 107. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 108. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 109. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Players (2016-2021) & (US$ Million)
Table 110. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 111. Neurodegenerative Disorder Therapeutics Market Trends
Table 112. Neurodegenerative Disorder Therapeutics Market Drivers
Table 113. Neurodegenerative Disorder Therapeutics Market Challenges
Table 114. Neurodegenerative Disorder Therapeutics Market Restraints
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Year-over-Year 2016-2027 & (US$ Million)
Figure 2. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 3. Global Neurodegenerative Disorder Therapeutics Market Share by Regions: 2021 VS 2027
Figure 4. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size Share by Region (2022-2027)
Figure 5. North America Neurodegenerative Disorder Therapeutics Market Size (US$ Million) Growth Rate (2016-2027)
Figure 6. Europe Neurodegenerative Disorder Therapeutics Market Size (US$ Million) and Growth Rate (2016-2027)
Figure 7. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (US$ Million) and Growth Rate (2016-2027)
Figure 8. Latin America Neurodegenerative Disorder Therapeutics Market Size (US$ Million) and Growth Rate (2016-2027)
Figure 9. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (US$ Million) and Growth Rate (2016-2027)
Figure 10. Global Neurodegenerative Disorder Therapeutics Market Size Share by Type in 2021 & 2027
Figure 11. Immunomodulators Market Size (US$ Million) YoY Growth (2016-2027)
Figure 12. Interferons Market Size (US$ Million) YoY Growth (2016-2027)
Figure 13. Decarboxylase Inhibitors Market Size (US$ Million) YoY Growth (2016-2027)
Figure 14. Dopamine Agonists Market Size (US$ Million) YoY Growth (2016-2027)
Figure 15. Others Market Size (US$ Million) YoY Growth (2016-2027)
Figure 16. Global Neurodegenerative Disorder Therapeutics Market Size Share by Application in 2021 & 2027
Figure 17. Multiple Sclerosis Market Size (US$ Million) YoY Growth (2016-2027)
Figure 18. Parkinson'S Disease Market Size (US$ Million) YoY Growth (2016-2027)
Figure 19. Alzheimer'S Disease Market Size (US$ Million) YoY Growth (2016-2027)
Figure 20. Spinal Muscular Atrophy Market Size (US$ Million) YoY Growth (2016-2027)
Figure 21. Huntington Disease Market Size (US$ Million) YoY Growth (2016-2027)
Figure 22. Other Neurodegenerative Disorders Market Size (US$ Million) YoY Growth (2016-2027)
Figure 23. Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 24. Global Top 5 and Top 10 Players Neurodegenerative Disorder Therapeutics Market Share in 2020
Figure 25. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 27. Canada Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 28. Germany Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 29. France Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 30. U.K. Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 31. Italy Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 32. Russia Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 33. Nordic Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 34. Rest of Europe Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2016-2027)
Figure 36. China Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 37. Japan Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 38. South Korea Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 39. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 40. India Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 41. Australia Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 42. Rest of Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 43. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 44. Mexico Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 45. Brazil Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 46. Rest of Latin America Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 48. Turkey Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 49. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 50. UAE Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 51. Rest of Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2016-2027) & (US$ Million)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Keyplayers in Global Neurodegenerative Disorder Therapeutics Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application
Biogen, Inc.Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
Request Sample
Request Discount
